Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer (Document Control Number : v3.0 930038662 2.0) + Administrative Letters 01 (version 1.0 dated 02-Jun-10) and 02 (version 1.0 dated 04-Nov-10)

Study of immunotherapy to treat advanced prostate cancer

Registry ID

EUCTR2009-016217-23

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Bristol-Myers Squibb International Corporation

Start date

2011-04-20

Last update

2026-08-16

Conditions

• Castration Resistant Prostate Cancer
• Castration Resistant Prostate Cancer Cancer de Prostata resistente a la castración

Summary

To compare overall survival of subjects with chemotherapy-naïve Castration Resistant Prostate Cancer (CRPC) who have been randomized to ipilimumab vs placebo.

Locations

• , , Sweden
• , , Netherlands
• , , UK
• , , Germany
• , , Czechia
• , , Spain
• , , Denmark
• , , Hungary
• , , Italy
• , , Greece

Related clinical trials

• Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

View on source registry